收费全文 | 61524篇 |
免费 | 2988篇 |
国内免费 | 408篇 |
耳鼻咽喉 | 568篇 |
儿科学 | 1270篇 |
妇产科学 | 763篇 |
基础医学 | 8034篇 |
口腔科学 | 1769篇 |
临床医学 | 3752篇 |
内科学 | 15584篇 |
皮肤病学 | 1294篇 |
神经病学 | 4382篇 |
特种医学 | 2131篇 |
外科学 | 11171篇 |
综合类 | 245篇 |
一般理论 | 4篇 |
预防医学 | 1740篇 |
眼科学 | 952篇 |
药学 | 4030篇 |
中国医学 | 213篇 |
肿瘤学 | 7018篇 |
2023年 | 293篇 |
2022年 | 231篇 |
2021年 | 1117篇 |
2020年 | 658篇 |
2019年 | 958篇 |
2018年 | 1221篇 |
2017年 | 1007篇 |
2016年 | 1142篇 |
2015年 | 1164篇 |
2014年 | 1585篇 |
2013年 | 2009篇 |
2012年 | 3235篇 |
2011年 | 3633篇 |
2010年 | 2121篇 |
2009年 | 1762篇 |
2008年 | 3255篇 |
2007年 | 3594篇 |
2006年 | 3443篇 |
2005年 | 3675篇 |
2004年 | 3541篇 |
2003年 | 3506篇 |
2002年 | 3478篇 |
2001年 | 1487篇 |
2000年 | 1516篇 |
1999年 | 1434篇 |
1998年 | 838篇 |
1997年 | 620篇 |
1996年 | 603篇 |
1995年 | 620篇 |
1994年 | 538篇 |
1993年 | 519篇 |
1992年 | 961篇 |
1991年 | 874篇 |
1990年 | 841篇 |
1989年 | 882篇 |
1988年 | 781篇 |
1987年 | 701篇 |
1986年 | 634篇 |
1985年 | 603篇 |
1984年 | 435篇 |
1983年 | 364篇 |
1982年 | 199篇 |
1981年 | 190篇 |
1980年 | 186篇 |
1979年 | 315篇 |
1978年 | 225篇 |
1977年 | 187篇 |
1974年 | 170篇 |
1973年 | 188篇 |
1972年 | 174篇 |
Osimertinib is effective in patients with T790M mutation-positive advanced non-small-cell lung cancer (NSCLC) resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). However, its effectiveness and safety in patients with poor performance status (PS) are unknown.
MethodsEnrolled patients showed disease progression after treatment with gefitinib, erlotinib, or afatinib; T790M mutation; stage IIIB, IV, or recurrent disease; and PS of 2–4. Osimertinib was orally administered at a dose of 80 mg/day. The primary endpoint of this phase II study (registration, jRCTs061180018) was response rate and the secondary endpoints were progression-free survival (PFS), overall survival (OS), disease control rate, and safety.
ResultsThirty-three patients were enrolled, of which 69.7% and 24.2% had PS of 2 and 3, respectively. One patient was excluded due to protocol violation; in the remaining 32 patients, the response rate was 53.1%; disease control rate was 75.0%; PFS was 5.1 months; and OS was 10.0 months. The most frequent adverse event of grade 3 or higher severity was lymphopenia (12.1%). Interstitial lung disease (ILD) was observed at all grades and at grades 3–5 in 15.2% (5/33) and 6.1% (2/33) of patients, respectively. Treatment-related death due to ILD occurred in one patient. Patients negative for activating EGFR mutations after osimertinib administration had longer median PFS than those positive for these mutations.
ConclusionOsimertinib was sufficiently effective in EGFR-TKI-resistant, poor PS patients with T790M mutation-positive advanced NSCLC. Plasma EGFR mutation clearance after TKI treatment could predict the response to EGFR-TKIs.
相似文献Methods: Individuals who visited the outpatient clinic or were admitted to the palliative care unit were eligible. Patients with a performance status of 4 and/or those unable to complete questionnaires were excluded. PA was evaluated using a bioanalyzer device. The correlation coefficient between PA and the variables of interest was analyzed.
Results: A total of 102 patients were analyzed. PA was weakly correlated with age (ρ = ?0.22), performance status (ρ = ?0.30), functional well-being (ρ?=?0.20), anorexia/cachexia subscale (ρ?=?0.22), and Functional Assessment of Anorexia/Cachexia Therapy trial outcome index (ρ?=?0.26). PA was also correlated with fluid retention (ρ = ?0.34) and albumin (ρ?=?0.32), C-reactive protein (ρ = ?0.31), and hemoglobin (ρ?=?0.41) levels. Sub-analysis stratified according to sex revealed that males demonstrated the same results; however, female sex demonstrated a correlation between PA and social well-being (ρ = ?0.43).
Conclusions: PA was correlated with physical condition, but not with psychological well-being. 相似文献